Previous Close | 0.2010 |
Open | 0.1960 |
Bid | 0.1620 x 1100 |
Ask | 0.1725 x 1000 |
Day's Range | 0.1784 - 0.2070 |
52 Week Range | 0.1500 - 1.8300 |
Volume | |
Avg. Volume | 4,010,285 |
Market Cap | 40.52M |
Beta (5Y Monthly) | 1.54 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0790 |
Earnings Date | Mar 01, 2022 - Mar 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.50 |
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.
Ampio Pharmaceuticals Inc's (NYSE: AMPE) independent special Committee of the Ampio Board of Directors has started an internal investigation regarding Ampio's AP-013 trial with the assistance of independent legal counsel. FDA has communicated to Ampio that it does not consider data from AP-013 to be sufficient to demonstrate efficacy as a second pivotal trial for Ampion. Further analysis suggests that data from AP-013 will not be sufficient to support regulatory approval in the US or other count
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results for the first quarter ended March 31, 2022.